GlassScriptPhysician profile
Margi Ashutosh Bhatt
NPI 1174594485
$3,844.02
in general payments reported to CMS, 2019-2025
38 companies · $420 in 2025
The $420 reported for 2025 was more than what 88% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $832 · 2020: $334 · 2021: $501 · 2022: $744 · 2023: $634 · 2024: $378 · 2025: $420.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,432.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,432.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $458.37 | 2019-2024 | Gardasil, Capvaxive, Gardasil 9 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $435.13 | 2019-2025 | Jardiance, Synjardy |
| Astellas Pharma US INC | $362.56 | 2019-2024 | Veozah, Myrbetriq |
| Lilly USA, LLC | $281.53 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $214.84 | 2019-2024 | Prolia, Evenity, Repatha |
| Sanofi-Aventis U.S. LLC | $201.01 | 2019-2025 | |
| Abbott Laboratories | $178.26 | 2021-2022 | |
| Glaxosmithkline, LLC. | $176.94 | 2019-2025 | Shingrix, Arexvy |
| Gilead Sciences, INC. | $165.28 | 2019-2023 | |
| Dexcom, INC. | $143.55 | 2021-2025 | Dexcom G6 Transmitter |
| Allergan, INC. | $140.61 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $128.08 | 2019-2025 | |
| Pfizer INC. | $105.21 | 2019-2025 | |
| Xeris Pharmaceuticals, INC. | $78.79 | 2022-2024 | Gvoke Hypopen |
| Abbvie INC. | $74.53 | 2021-2025 | Qulipta |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $70.46 | 2019 | |
| Novo Nordisk INC | $52.76 | 2019-2022 | |
| Lifescan, INC. | $46.05 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $45.89 | 2019-2022 | |
| Boston Scientific Corporation | $45.44 | 2019-2024 | Watchman Flx |
| Lucid Diagnostics INC. | $42.56 | 2022 | |
| Edwards Lifesciences Corporation | $42.45 | 2023-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Ascensia Diabetes Care US INC. | $39.66 | 2023-2024 | |
| Paratek Pharmaceuticals, INC. | $32.92 | 2023-2025 | Nuzyra |
| Bayer Healthcare Pharmaceuticals INC. | $30.51 | 2022-2025 | |
| Sanofi Pasteur INC. | $26.88 | 2019-2020 | |
| Tetraphase Pharmaceuticals, INC. | $26.10 | 2020 | |
| Daiichi Sankyo INC. | $23.53 | 2021 | |
| Viiv Healthcare Company | $22.14 | 2025 | Apretude |
| Sequel Med Tech, LLC | $20.51 | 2025 | Twiist |
| Actelion Pharmaceuticals US, INC. | $19.72 | 2024 | Opsumit |
| Kyowa Kirin, INC. | $19.37 | 2023 | Crysvita |
| Corcept Therapeutics | $17.62 | 2024 | Korlym |
| Medtronic, INC. | $16.94 | 2025 | Minimed 780g |
| Insmed, INC. | $16.86 | 2021 | |
| Shionogi INC | $14.67 | 2021 | |
| Antares Pharma, INC. | $14.52 | 2019 | |
| Janssen Biotech, INC. | $11.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Margi Bhatt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.